BEAM vs RLAY: Which Stock Is the Better Buy?
Beam Therapeutics Inc. and Relay Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BEAM vs RLAY, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Beam Therapeutics Inc. (BEAM) | Relay Therapeutics, Inc. (RLAY) | |
|---|---|---|
| Market cap | $3.0B | $3.1B |
| Revenue (latest FY) | $139.74M | $15.36M |
| Net income (latest FY) | $-79.99M | $-276.48M |
| Revenue growth (5y CAGR) | 466.3% | -28.6% |
| Net margin | -57.2% | -1800.6% |
| Return on equity | -6.5% | -48.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BEAM vs RLAY breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BEAM's full financials → Open RLAY's full financials →More comparisons
Frequently asked questions
Which is bigger, BEAM or RLAY?
Relay Therapeutics, Inc. is larger by market capitalization — $3.1B versus $3.0B.
Which grows faster, BEAM or RLAY?
Over the last five fiscal years, Beam Therapeutics Inc. grew revenue faster — 466.3%/yr versus -28.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
BEAM fundamentals → · RLAY fundamentals → · All 1,500+ companies → · Free screener →